Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritonavir and Indinavir in Children Failing Other Antiretroviral Therapy
NCT00012519Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of indinavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Tolerability at 24 months and Pharmacokinetics at Week 16. Status: completed.
02
Drugs
indinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00012519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012519.